Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Alpha-taxilin (TXLNA) is a member of the taxilin protein family, which also includes beta- and gamma-taxilin. It binds to members of the syntaxin family and regulates intracellular vesicle transport by interfering with SNARE complex formation, thereby modulating vesicle trafficking[2][4]. Alpha-taxilin is also known as interleukin-14 and controls proliferation of normal and malignant B-cells, acting as a cytokine predominantly produced by T-cells and malignant B-cells[3]. Recent research has revealed a structural role for alpha-taxilin at centriolar subdistal appendages (SDA), contributing to centrosomal microtubule anchorage and spindle orientation during cell division[1]. Reduced alpha-taxilin levels are observed in HCV infection, and its overexpression limits viral particle release, highlighting a role in infection biology[2]. Alpha-taxilin seems to function in multiple cell types, integrating trafficking, cytoskeleton, and immune growth factor signaling[1][2][3][4].
Drugs targeting alpha-taxilin would likely modulate vesicular trafficking (e.g. SNARE-mediated fusion inhibition) and could have potential indirect antiviral mechanisms by preventing viral particle release.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Alpha-taxilin (TXLNA).